Amneal Pharmaceuticals of New York, LLC

Amneal Pharmaceuticals of New York, LLC is a Delaware-formed operating subsidiary of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX), a publicly traded global biopharmaceutical company founded in 2002 by brothers Chirag and Chintu Patel and headquartered at 400 Crossing Boulevard, Bridgewater, New Jersey. The New York LLC entity itself was formed in 2008 and operates Amneal's New York manufacturing footprint, including a facility in Brookhaven, NY. Amneal reported roughly $3.0B in net revenue for FY2025, about 8,500–8,700 employees, and a market capitalization near $6.1B as of mid-2026; it became a conventional C-corporation after a 2023 reorganization that eliminated its up-C structure (SEC 10-K).

Amneal develops, manufactures, markets, and distributes medicines through three reportable segments: Affordable Medicines (retail generics, sterile injectables, and biosimilars — roughly 280 product families spanning oral solids, liquids, nasal sprays, inhalation products, ophthalmics, transdermal patches, and topicals); Specialty (branded CNS and endocrine products, including CREXONT, RYTARY, UNITHROID, and ONGENTYS); and AvKARE (repackaging and wholesale distribution of pharmaceuticals and medical/surgical products, mainly to the U.S. Department of Defense and Department of Veterans Affairs). It operates primarily in the U.S., India, and Ireland.

Litigation posture: one tracked case, and Amneal is the defendant, with zero plaintiff-side filings. That pattern is consistent with an operating company defending pharmaceutical patent suits rather than a patent assertion entity. The lone tracked matter, Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals of New York, LLC (D. Del., filed 2018-12-20), is the familiar Hatch-Waxman/ANDA form of generic-versus-brand infringement dispute; Amneal's broader portfolio of such suits (e.g., earlier matters involving Amgen and Meda) follows the same pattern. The venue is the District of Delaware, a common forum for pharmaceutical patent litigation, not a notably plaintiff-friendly NPE venue such as the Eastern District of Texas. No tracked case characterizes Amneal as an acquirer or asserter of patents.